SPINK1 and myelodysplastic syndrome: In the last decades, numerous LSD1 inhibitors, including TCP, ORY-1001, ORY-2001, CC-90011, INCB059872, and IMG-7289 are undergoing clinical trials for treatment of AML, myelodysplastic syndromes (MDS), myeloproliferative neoplasms, SCLC, relapsed Ewing sarcoma, myelofibrosis, essential thrombocythemia, multiple sclerosis, mild to moderate Alzheimer’s disease [11].